Cargando…
Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treat...
Autores principales: | Iwamoto, Takuya, Maeda, Masaki, Hisanaga, Takuro, Saeki, Issei, Fujisawa, Koichi, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109555/ https://www.ncbi.nlm.nih.gov/pubmed/27746425 |
Ejemplares similares
-
Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2019) -
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
por: Saeki, Issei, et al.
Publicado: (2018) -
Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report
por: Iwamoto, Takuya, et al.
Publicado: (2019) -
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016) -
Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model
por: Tanabe, Norikazu, et al.
Publicado: (2017)